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Abstract. The mTOR inhibitor temsirolimus has antitumor 
and antiangiogenic activity against several carcinomas, yet few 
reports document the efficacy of temsirolimus against malig-
nant pleural mesothelioma (MPM). Therefore, we evaluated 
the efficacy of temsirolimus and the antiangiogenic effect of 
temsirolimus in the treatment of MPM. We examined the effi-
cacy of temsirolimus alone and the efficacy of the combination 
of temsirolimus and cisplatin or pemetrexed against four MPM 
cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay. The effect of temsirolimus 
on the production of proangiogenic cytokines by MPM cell 
lines was examined by enzyme-linked immunosorbent assay 
(ELISA). Expression of mTOR and proangiogenic cytokines 
in clinical specimens from MPM patients was determined by 
immunohistochemistry. Temsirolimus inhibited cell viability 
and suppressed cell proliferation of all MPM cell lines. 
Combined treatment with temsirolimus and cisplatin inhib-
ited the viability of all MPM cell lines more effectively than 
temsirolimus alone. Temsirolimus strongly inhibited the phos-
phorylation of p70s6k, a downstream molecule of mTOR, in all 
MPM cell lines and led to an increase in the levels of cleaved 
caspase-3 in the H226 and Y-meso14 cells. Temsirolimus also 
inhibited the production of vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor-AA (PDGF-AA). 
Phosphorylated mTOR and high expression of VEGF and 
PDGF were detected in 2 and 3, respectively, out of the 5 
MPM specimens. These results suggest that temsirolimus has 
activity against MPM cells by inhibition of cell proliferation 
and angiogenesis, and may be beneficial for a subset of MPM 
patients with high mTOR expression.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive 
cancer arising from the surface serosal cells of pleural cavities. 
MPM is associated with exposure to asbestos fibers. MPM 
is highly resistant to conventional chemotherapy and radio-
therapy, and has an extremely poor prognosis; median survival 
is 4-13 months for untreated patients (1) and 6-18 months for 
treated patients (2,3). Although platinum-based chemotherapy 
is used widely, it has a modest therapeutic effect. Hence, iden-
tification of new agents that enhance its therapeutic effect is 
warranted.
The mammalian target of rapamycin (mTOR) is a 289-kDa 
serine-threonine kinase that was identified as a target molecule 
of rapamycin (a macrolide fungicide isolated from the bacteria 
Streptomyces hygroscopicus). mTOR is a member of the large 
phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) 
family of protein kinases, and is located downstream of the 
PI3K/Akt signaling pathway. Growth factors such as insulin-
like growth factor (IGF), epidermal growth factor (EGF) 
and vascular endothelial growth factor (VEGF) regulate 
mTOR signals through the PI3K/Akt signaling pathway (4). 
Rapamycin inhibits mTOR by binding to its immunophilin, 
FK506-binding protein 12 (FKBP12), and blocks progres-
sion from the G1 phase to the S phase of the cell cycle and 
induces the apoptosis of tumor cells (5). mTOR also plays a 
key role in angiogenesis. mTOR increases the translation of 
hypoxia-inducible factor 1 (HIF-1)/HIF-2. A major role of 
the HIF transcription factors is to upregulate transcription 
of mitogenic growth factors such as VEGF which lead to 
angiogenesis (6).
Temsirolimus, a water-soluble dihydroester analog of 
rapamycin, has been approved for renal cell carcinoma and 
breast cancer, based on the results of a randomized phase III 
study (7) and a phase II study (8), respectively. Recent studies 
have demonstrated that mTOR inhibitors are useful for the 
treatment of MPM (9,10). Several studies have suggested 
that temsirolimus inhibits angiogenesis through inhibition 
of HIF-1-dependent VEGF production in breast cancer and 
multiple myeloma (6,11).
In the present study, we evaluated the benefits of temsiro-
limus against MPM cell lines and the efficacy of combination 
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therapy with cisplatin or pemetrexed (which are presently used 
as therapeutic agents for MPM) and assessed the antiangio-
genic effect of temsirolimus against MPM in vitro.
Materials and methods
Cell lines and culture conditions. The MPM cell lines H290 
and Y-meso14 as well as the human mesothelial cell line 
Met-5A were kindly provided by Dr Sekido (Aichi Cancer 
Center Research Institute, Nagoya, japan). The MPM cell lines 
H226 and MSTO-211H as well as the human lung fibroblast cell 
lines MRC-5 and IMR-90 were purchased from the American 
Type Culture Collection (ATCC; Manassas, VA, uSA). Cells 
were maintained in specific media during incubation at 37˚C in 
a humidified atmosphere of 5% CO2 in air. Four human MPM 
cell lines and MeT-5A were cultured in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS). MRC-5 and 
IMR-90 were cultured in Dulbecco's modified Eagle's medium 
(DMEM) with 10% FBS. Each medium contained 100 U/ml of 
penicillin and 0.1 mg/ml of streptomycin.
Drugs. Temsirolimus was obtained from Pfizer (New York, 
NY, uSA), cisplatin was from Nippon Kayaku (Tokyo, 
japan), and pemetrexed was from Eli Lilly (Tokyo, japan). 
Temsirolimus was stored as a 1-mM solution in dimethyl sulf-
oxide (DMSO) at -20˚C, cisplatin was stored as an undiluted 
solution (0.5 mg/ml) at -20˚C, and pemetrexed was stored as 
a solution of concentration 1 mg/ml in physiological (0.9%) 
saline at -20˚C.
Cell viability and proliferation assays. Cell viability was 
measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) dye reduction method (12). In 
brief, cells were seeded onto 96-well plates (2,000 cells/well) 
in 100 µl RPMI-1640 or DMEM with 10% FBS for 24 h. 
Afterward, the cells were exposed either to temsirolimus 
alone (at concentrations ranging from 0 to 10 µM), cisplatin 
(0-10 µg/ml) or pemetrexed (0-10 µg/ml) for 72 h at 37˚C with 
5% CO2 or combinations of the agents. In addition, 50 µl of a 
stock MTT solution (2 mg/ml) was added to all of the wells, 
and the cells were incubated for 2 h at 37˚C with 5% CO2. 
The media containing the MTT solution were removed and 
the dark-blue crystals dissolved by adding 100 µl DMSO. 
Absorbance was measured at a wavelength of 570 nm with a 
microplate reader.  Cell proliferation was determined by cell 
counting. Cells were seeded onto 6-well plates (10,000 cells/
well) and incubated for the indicated periods. After cells were 
harvested, the cell number was counted.
Determination of protein levels of VEGF and platelet-derived 
growth factor-AA (PDGF-AA). Culture supernatants were 
evaluated. For culture supernatants, tumor cells were seeded 
into 6-well plates at 2x105 cells/well in 2 ml of RPMI-1640 
medium with 10% FBS and exposed to temsirolimus (0-1 µM) 
for 48 h. The supernatants were harvested, and the levels 
of VEGF and PDGF-AA were determined using enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems, 
Minneapolis, MN, uSA) according to the manufacturer's 
instructions. The lower limit of detection was 31.2 pg/ml for 
VEGF and 31.2 pg/ml for PDGF-AA.
Antibodies and western blot analyses. Tumor cells were 
incubated in 10 ml of RPMI-1640 buffer with 10% FBS in 
temsirolimus (0-1 µM) for 1 h. The total protein level was 
measured using a bicinchoninic acid (BCA) protein assay kit 
(Pierce Biotechnology, Rockford, IL, uSA). For western blot 
analyses, 40 µg of total protein was resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Bio-Rad Laboratories, waltham, MA, uSA). The proteins 
were transferred onto polyvinylidene difluoride membranes 
(Bio-Rad Laboratories). The following primary antibodies 
were used: anti-phospho-S6 ribosomal protein; anti-S6 ribo-
somal protein, or anti-cleaved caspase 3 (Asp175) antibodies 
(1:1,000 dilution; Cell Signaling Technology, Beverly, MA, 
uSA) and anti-G3PDH polyclonal antibody (1:1,000 dilution; 
Trevigen, El Paso, TX, uSA). Membranes were incubated for 
1 h at room temperature with species-specific horseradish 
peroxidase-conjugated secondary antibodies. Immunoreactive 
bands were visualized with SuperSignal west Dura Extended 
Duration Substrate Enhanced Chemiluminescent Substrate 
(Pierce Biotechnology). Each experiment was carried out 
independently in triplicate.
Immunohistochemical analyses. Five tumor specimens were 
obtained from 5 MPM patients, all of whom provided written 
informed consent, at the Kanazawa university Hospital. The 
present study was approved by the Institutional Review Boards 
of the Kanazawa university.
Paraffin sections were autoclaved and immunostained with 
the following primary antibodies: mTOR (mTOR/FRAP; rabbit 
monoclonal; 1:350 dilution; Epitomics, San Francisco, CA, 
uSA), anti-phospho-mTOR [mTOR/FRAP phospho (pS2448); 
rabbit monoclonal; 1:100 dilution; Epitomics], anti-VEGF 
(rabbit polyclonal; 1:100 dilution; Santa Cruz Biotechnology, 
Santa Cruz, CA, uSA), and anti-PDGF-AA (rabbit polyclonal; 
1:200 dilution; EMD Millipore Corp., waltham, MA, uSA). 
Antibodies were visualized by a ChemMate EnVision/
peroxidase complex kit (Dako, Tokyo, japan). The ‘immu-
nohistochemical expression level’ was scored by a three-tier 
system: negative expression (score 0), <10%; low expression 
(score 1), ≥10% but <50%; high expression (score 2), ≥50% 
tumor cells with ‘significant’ staining (13).
Statistical analyses. Statistical analyses were carried out using 
GraphPad Prism ver 5.02. The statistical significance of differ-
ences between control and test values was analyzed using 
Student's t-test, Mann-whitney u test, and one-way analysis 
of variance (ANOVA) with Bonferroni's post hoc test, where 
applicable. Differences at P<0.05 were deemed significant.
Results
Effects of temsirolimus, cisplatin or pemetrexed on MPM cell 
lines. Temsirolimus treatment for 72 h inhibited the viability 
of all MPM cell lines in a concentration-dependent manner 
(Fig. 1A). The half-maximal inhibitory concentration (IC50) 
of temsirolimus in H226, H290, Y-meso14 and MSTO-211H 
cells was ~2, 0.5, 0.5 and 0.2 µM, respectively. Temsirolimus 
also inhibited the cell numbers of all MPM cell lines tested 
(Fig. 2), indicating that temsirolimus suppressed cell prolif-
eration of the MPM cell lines. Cisplatin also inhibited the 

























































































































viability of all MPM cell lines. The IC50 of cisplatin in H226, 
H290, Y-meso14 and MSTO-211H cells was ~2, 0.5, 0.7 and 
0.4 µg/ml, respectively. Pemetrexed moderately inhibited the 
viability of MPM cell lines when compared with the effect of 
the other two drugs except for MSTO-211H cells. The IC50 of 
pemetrexed in MSTO-211H cells was ~0.04 µg/ml, whereas it 
was >10 µg/ml in the other three cell lines.
Effect of temsirolimus, cisplatin or pemetrexed on MRC-5, 
IMR-90 and Met-5A as ‘non-neoplastic cells’. Temsirolimus-
induced inhibition of the viability of non-neoplastic cells 
was less compared with that of the MPM cell lines (Fig. 1B). 
Cisplatin displayed strong inhibition of the viability of Met-5A 
cells, but less inhibition of the other cell lines. Pemetrexed 
showed slight inhibition of the viability of Met-5A cells, but 
not MRC-5 or IMR-90 cells.
Effects of a combined treatment of temsirolimus and cisplatin 
or the combined treatment of temsirolimus and pemetrexed on 
the viability of MPM cell lines. To examine the effect of temsi-
rolimus combined with cisplatin or pemetrexed on MPM cell 
lines, cells were cultured with combinations of temsirolimus 
(0-10 µM) and cisplatin (0.1 and 0.3 µg/ml) or pemetrexed (0.1 
and 0.3 µg/ml) for 72 h. MSTO-211H cells demonstrated high 
sensitivity to pemetrexed, thus the MSTO-211H cell line was 
excluded from combination treatment with temsirolimus and 
pemetrexed. The dose-response curves of the combination 
treatment are depicted in Fig. 3A. Combination treatment with 
temsirolimus and cisplatin inhibited the viability of all MPM 
cell lines more effectively than temsirolimus alone. when the 
effect of the combination treatment of 0.01 µM temsirolimus 
and 0.3 µg/ml cisplatin was compared with 0.01 µM temsi-
rolimus alone or 0.3 µg/ml cisplatin alone, the combination 
Figure 1. Effect of temsirolimus, cisplatin, and pemetrexed on the viability of MPM cell lines and non-neoplastic cells. (A) H226 (●), H290 (○), Y-meso14 (◼) 
and MSTO-211H (□) (2x103/well) cells were incubated for 72 h with temsirolimus (0-10 µM), cisplatin (0-10 µg/ml) or pemetrexed (0-10 µg/ml). (B) MRC-5 
(▲), IMR-90 (∆) and Met-5A (◆) (2x103/well) cells were incubated for 72 h with temsirolimus (0-10 µM), cisplatin (0-10 µg/ml), or pemetrexed (0-10 µg/ml). 
Points, mean of quintet cultures; bars, SD.
Figure 2. Effect of temsirolimus on the proliferation of MPM cell lines. MPM cell lines were incubated for the indicated periods with or without temsirolimus 
(control, ○; 10 nM, ●; 100 nM, ◼). After cells were harvested, the cell number was counted. Points, mean of quintet cultures; bars, SD.

























































































































treatment was significantly more effective wheb compared 
with each drug alone in all MPM cell lines (Fig. 3B). There 
was no significant difference between the combination treat-
ment of 0.01 µM temsirolimus and 0.3 µg/ml pemetrexed with 
pemetrexed alone in the H226 cells or with temsirolimus alone 
in the H290 cells (data not shown). Compared with each drug 
alone, the combination of temsirolimus and pemetrexed was 
more effective only in the Y-meso14 cells.
Effect of temsirolimus on proangiogenic cytokine production 
in the MPM cell lines. To examine the effect of temsirolimus 
on the release of proangiogenic cytokines in the MPM cell 
lines, tumor cells were exposed to temsirolimus (0-1 µM) and 
the levels of VEGF and PDGF-AA in the supernatants were 
measured by ELISA. Temsirolimus strongly inhibited VEGF 
production (Fig. 4A), and moderately inhibited the production 
of PDGF-AA in all four MPM cell lines (Fig. 4B).
Figure 3. Effects of temsirolimus combined with cisplatin or pemetrexed upon proliferation of MPM cell lines. (A) MPM cell lines were incubated for 72 h 
with temsirolimus (0-10 µM) and cisplatin (0.1 or 0.3 µg/ml). Cisplatin-free (●), 0.1 µg/ml cisplatin (○), 0.3 µg/ml cisplatin (◼). (B) Combination of temsirolimus 
(Tem) (0.01 µM) and cisplatin (Cis) (0.3 µg/ml) in MPM cell lines. The significance of the difference between the control and test values was determined by 
the two-tailed multiple t-test with Bonferroni correction following ANOVA (three comparisons in four groups). Columns, mean of quintet culture; bar, SD; 
*P<0.05, **P<0.01, ***P<0.001.
Figure 4. Effect of temsirolimus on the production of proangiogenic cytokines in MPM cell lines. (A) VEGF protein secretion by MPM cell lines as measured 
by ELISA. (B) PDGF-AA protein secretion by MPM cell lines as measured by ELISA. Columns, mean of representative of three independent experiments 
with similar results; bars, SD.

























































































































Effect of temsirolimus on the downstream proteins of mTOR 
signaling. western blot analyses showed that temsirolimus 
strongly inhibited the phosphorylation of S6 ribosomal protein 
(a kinase regulated by mTOR). The level of cleaved caspase-3 
(a known marker of apoptosis) increased in a dose-dependent 
manner in the H226 and Y-meso14 cells, but not in the MSTO-
211H and H290 cells, following treatment with temsirolimus 
(Fig. 5).
Immunohistochemical expression of mTOR, p-mTOR, 
VEGF and PDGF-AA in MPM tissues. mTOR immunohis-
tochemical staining exhibited an appreciable expression and 
cytoplasmic staining pattern in three of five MPM tissues 
(Fig. 6A-a and B). p-mTOR immunohistochemical staining 
also demonstrated a cytoplasmic pattern, and was observed 
in two of five MPM tissues (Fig. 6A-b and B). VEGF and 
PDGF-AA were expressed in the cytoplasm of numerous cells 
Figure 5. western blot analyses of the downstream proteins of mTOR signaling after incubation of MPM cell lines with temsirolimus. MPM cell lines were 
incubated with temsirolimus (0-1 µM) for 1 h. G3PDH polyclonal antibody served as a loading control.
Figure 6. (A) Immunohistochemical expression of mTOR (a), p-mTOR (b), VEGF (c), and PDGF-AA (d) in MPM tissues. (B) Summary of immunohisto-
chemical expression of mTOR, p-mTOR, VEGF and PDGF-AA in MPM tissues. The immunohistochemical reaction was evaluated according to the extent of 
positive staining using the following score: negative expression (score 0, <10% positive cells); low expression (score 1, 10-50% positive cells); high expression 
(score 2,  >50% positive cells).

























































































































and in the nuclei of some cells in four of five MPM tissues 
(Fig. 6A-c, d and B).
Discussion
In the present study, we demonstrated that temsirolimus 
inhibited the proliferation of MPM cells and that combined 
treatment with temsirolimus and cisplatin (a standard chemo-
therapeutic agent for MPM) resulted in greater cell death in 
the MPM cell lines.
Temsirolimus is a water-soluble dihydroester analog 
of rapamycin and is being developed for the treatment of 
cancer. Temsirolimus was approved by the uS Food and 
Drug Administration (FDA) for the treatment of advanced 
renal cell carcinoma (RCC) in 2007 as efficacy and safety 
were demonstrated at a second interim analysis of a phase 
III, multicenter, international, randomized and open-label 
study (7). In addition to RCC, several clinical trials were 
conducted in diverse types of carcinoma, such as breast 
cancer (8) and glioblastoma (14).
Several reports have focused on the effect of mTOR inhibi-
tors on MPM. Hartman et al (9) demonstrated that sirolimus 
(previously known as rapamycin) inhibited the proliferation of 
MPM cell lines, and that a combined treatment of sirolimus 
and cisplatin led to greater cell death in MPM cell lines. 
Hoda et al (10) reported that temsirolimus attenuated MPM 
cell growth in vitro and tumor formation in vivo, and it syner-
gized with cisplatin against MPM models in vitro and in vivo. 
mTOR is a protein kinase located downstream of the 
PI3K/Akt signaling pathway, which has an important role in the 
survival and proliferation of cells. Temsirolimus gains func-
tion by binding to FKBP12 and this complex inhibits mTOR 
kinase activity, consequently inhibiting phosphorylation of the 
40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic 
initiation factor 4E-binding protein-1 (4E-BP1) (15). Inhibition 
of these elements results in a decrease in protein synthesis and 
translation of specific mRNA species, and interferes with the 
progression from the G1 phase to S phase of the cell cycle (5). 
Temsirolimus also inhibits the translation of HIF-1/HIF-2, 
which upregulate the transcription of mitogenic growth 
factors such as VEGF and PDGF (6). In western blot analysis, 
phosphorylation of mTOR was observed in MPM specimens 
and temsirolimus strongly inhibited the phosphorylation of 
p70s6k (which is located downstream of mTOR) in all MPM 
cell lines in a dose-dependent manner. These data suggest that 
temsirolimus treatment inhibits the proliferation of tumor cells 
by inhibiting the phosphorylation of mTOR by inhibiting the 
activity of mTOR kinase. Temsirolimus treatment led to an 
increase in the level of cleaved caspase-3 (considered to be a 
marker of apoptosis) in H226 and Y-meso14 cells, but did not 
lead to an increase in the H290 and MSTO-211H cells. On the 
other hand, MTT assay showed that MSTO-211H cells had the 
most sensitivity to temsirolimus treatment. These data indicate 
that, in MSTO-211H and H290 cells, temsirolimus treatment 
did not induce apoptosis, but strongly obstructed cell prolifera-
tion. As expected, temsirolimus inhibited the cell count of all 
MPM cell lines tested. In contrast, Schedel et al (16) reported 
that temsirolimus significantly reduced cell viability and 
induced apoptosis and cell cycle arrest in bladder cancer and 
head and neck squamous cell carcinoma.
MPM is highly resistant to conventional chemotherapy. 
Cisplatin is one of the most effective chemotherapeutic 
agents against MPM but, if used alone, its response rate 
against MPM has been shown to be only 16.7%, with a 
median survival time of 9.3 months (17). when used in 
combination with the multitargeted antifolate agent peme-
trexed, the response rate increased significantly to 41.3% 
and the median survival time was significantly prolonged to 
12.1 months; however, the difference was only 2.8 months. 
Therefore, the identification of new agents is warranted. In 
the present study, we evaluated the therapeutic efficacy of the 
combined treatment of temsirolimus and cisplatin in MPM 
cell lines. Combination treatment with temsirolimus and 
cisplatin inhibited the viability of all MPM cell lines more 
effectively than treatment with temsirolimus alone. Hence, a 
synergistic or additive effect for the combination treatment 
of temsirolimus and cisplatin can be hypothesized, in accor-
dance with another report (10).
Rapidly proliferating tumors require an efficient blood 
supply to meet their nutritional needs; therefore, angiogen-
esis is essential for the growth and metastasis of tumors (18). 
VEGF is one of the most potent stimulators of angiogenesis, 
and high expression of VEGF is associated with intratu-
moral microvessel density and a poor prognosis in various 
types of carcinomas (19,20). PDGF has also been shown 
to support growth, angiogenesis and stroma recruitment in 
various tumor types (21,22). Del Bufalo et al (6) reported 
that temsirolimus may potently inhibit angiogenesis by 
multiple mechanisms: indirectly through transcriptional 
inhibition of hypoxia-stimulated, HIF-1α-dependent VEGF 
production as well as directly through inhibition of the 
endothelial cell functions involved in neoangiogenesis (e.g., 
growth factor-stimulated proliferation and morphogenesis). 
Other authors have reported that an mTOR inhibitor inhibits 
tumor growth by an antiangiogenic effect or by tumor-
specific thrombosis associated with a decrease in VEGF 
production (23). In accordance with our previous studies 
(24,25), tumor progression of Y-meso14 and EHMES-10 
(human MPM cell lines), which expressed high levels of 
VEGF, was inhibited by bevacizumab (an anti-VEGF anti-
body) or E7080 (a multi-tyrosine kinase inhibitor) in vivo. In 
contrast, the tumor progression of MSTO-211H cells (which 
expressed low levels of VEGF) was not inhibited by treat-
ment with bevacizumab. In the present study, we showed that 
temsirolimus strongly inhibited the production of VEGF in 
all four MPM cell lines tested. Temsirolimus is expected to 
inhibit the growth of VEGF-high-producing tumors (e.g., 
Y-meso14), due not only to an anticancer effect but also an 
antiangiogenic effect in vivo.
In summary, our results suggest that the mTOR inhibitor 
temsirolimus inhibits the proliferation of MPM cells, and 
strengthens the effect of platinum-based chemotherapy. The 
treatment effect resulted in dephosphorylation of the down-
stream proteins of the PI3K/Akt signaling pathway. In addition, 
the antiangiogenic effects may contribute substantially to the 
antitumor activity of tumors producing high levels of VEGF, 
such as in Y-meso 14 cells. Temsirolimus may be beneficial 
for a subset of MPM patients with high mTOR expression. we 
intend to investigate the effect of temsirolimus treatment in a 
MPM model in vivo.
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